SETTLEMENT AGREEMENT BY AND BETWEEN SUPERNUS PHARMACEUTICALS, INC. AND ZYDUS PHARMACEUTICAL (USA) INC. ZYDUS LIFESCIENCES LIMITED DATED AS OF DECEMBER 31, 2022License Agreement • March 9th, 2023 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SETTLEMENT AGREEMENT, (this “Zydus 200 mg Product Settlement Agreement”) is entered into as of December 31, 2022 (the “Effective Date”) by and between, Supernus Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having offices located at 9715 Key West Avenue, Rockville, Maryland 20850 (“Supernus”), on the one hand, and Zydus Pharmaceutical (USA) Inc., a corporation organized and existing under the laws of New Jersey having offices located at 73 Route 31 N., Pennington, New Jersey 08534 (“Zydus USA”) and Zydus Lifesciences Limited, a corporation formerly known as Cadila Healthcare Limited organized and existing under the laws of India, having offices located at Zydus Corporate Park, Scheme No. 63, Khoraj (Gandhinagar), 536, Sarkhej - Gandhinagar Hwy, Near Vaishnodevi Circle, Ahmedabad, Gujarat 382481, India (“Zydus Lifesciences” and together with Zydus USA, “Zydus”), on the other hand. Supernus and Zydus are collectively referred to herein as th
